cablivi - caplacizumab
(Caplacizumab)Genzyme Corporation
Usage: CABLIVI is indicated for adults and pediatric patients aged 12 and older with acquired thrombotic thrombocytopenic purpura (aTTP), to be used in conjunction with plasma exchange and immunosuppressive therapy.